Klaria Pharma Holding AB (publ.)
$0.85-0.47%($-0.00)
TickerSpark Score
55/100
20
Valuation
60
Profitability
100
Growth
36
Health
60
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLAR.ST research report →
52-Week Range49% of range
Low $0.39
Current $0.85
High $1.33
Companywww.klaria.com
Klaria Pharma Holding AB (publ. ) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy.
- CEO
- Scott Boyer
- IPO
- 2015
- Employees
- 4
- HQ
- Uppsala, SE
Price Chart
-5.13% · this period
Valuation
- Market Cap
- $290.70M
- P/E
- -4.05
- P/S
- 32.30
- P/B
- -40.57
- EV/EBITDA
- -20.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.83%
- Op Margin
- -280.41%
- Net Margin
- -432.22%
- ROE
- 970.98%
- ROIC
- 773.67%
Growth & Income
- Revenue
- $9.00M · 300.36%
- Net Income
- $-38,900,000 · 18.53%
- EPS
- $-0.21 · 44.74%
- Op Income
- $-25,237,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $1.33
- 52W Low
- $0.39
- 50D MA
- $0.90
- 200D MA
- $0.72
- Beta
- 1.20
- Avg Volume
- 760.40K
Get TickerSpark's AI analysis on KLAR.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KLAR.ST Coverage
We haven't published any research on KLAR.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KLAR.ST Report →